Development and validation of an enzyme immunoassay for detection and quantification of SARS-CoV-2 salivary IgA and IgG

Oral fluids offer a non-invasive sampling method for the detection of antibodies. Quantification of IgA and IgG antibodies in saliva allows studies of the mucosal and systemic immune response after natural infection or vaccination. We developed and validated an enzyme immunoassay (EIA) to detect and quantify salivary IgA and IgG antibodies against the prefusion-stabilized form of the SARS-CoV-2 spike protein. Normalization against total antibody isotype was performed to account for specimen differences, such as collection time and sample volume. Saliva samples collected from 187 SARS-CoV-2 confirmed cases enrolled in 2 cohorts and 373 pre-pandemic saliva samples were tested. The sensitivity of both EIAs was high (IgA: 95.5%; IgG: 89.7%) without compromising specificity (IgA: 99%; IgG: 97%). No cross reactivity with seasonal coronaviruses was observed. The limit of detection for SARS-CoV-2 salivary IgA and IgG assays were 1.98 ng/mL and 0.30 ng/mL, respectively. Salivary IgA and IgG antibodies were detected earlier in patients with mild COVID-19 symptoms than in severe cases. However, severe cases showed higher salivary antibody titers than those with a mild infection. Salivary IgA titers quickly decreased after 6 weeks in mild cases but remained detectable until at least week 10 in severe cases. Salivary IgG titers remained high for all patients, regardless of disease severity. In conclusion, EIAs for both IgA and IgG had high specificity and sensitivity for the confirmation of current or recent SARS-CoV-2 infections and evaluation of the IgA and IgG immune response.


Footnote page 22
Financial support 23 This work was supported in part by federal funds from the National Institute of Allergy and Infectious 24 Diseases NIAID R01AI145835 (W. M) 25 Potential conflicts of interest 26 All authors reported no potential conflicts of interest. individuals not only results in a high transmission rate, but also suggests differences in the host immune 66 response compared to other coronaviruses [5]. Since the duration of immunity to SARS-CoV-2 dictates  Salivary antibody levels can be 100 to 1000-fold lower than serum levels [7]. Salivary IgG is 74 mainly derived from serum by leakage across capillaries and enters saliva through gingival crevices. At 75 mucosal membranes, IgA is the main immunoglobulin class and is found most often in the secretory 76 form (sIgA). Within 2-3 weeks after onset of disease, SARS-CoV-2-specific IgG antibodies can be 77 detected in saliva, persist for at least 9 months, and show high correlation with serum antibody levels in 78 most COVID-19 patients [8][9][10][11]. Salivary IgA antibodies, on the contrary, rapidly increase 1 week after 79 onset of disease, become undetectable 4-5 weeks later, and show a moderate correlation with serum 80 levels [8,9]. Saliva provides a non-invasive collection method, easy to implement in remote areas and 81 community settings without a need for extensive training. These features, while additionally evaluating 82 both mucosal and systemic immune responses, make salivary antibody testing an ideal approach to 83 evaluate population immunity, transmission, asymptomatic infections, and vaccine performance. 84 We previously demonstrated the value of saliva-based antibody assays to evaluate immune responses 85 mounted against norovirus [12]. In this manuscript, we describe the development and validation of an  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   Specimen collection and processing 104 Saliva was collected at least 30 minutes after consumption of food or liquids. Pre-pandemic 105 archived saliva samples were collected using the Oracol saliva collection device, processed, and stored 106 at -80°C according to the manufacturer's instructions (Malvern Medical Developments, Worcester, UK).

107
Cohort I samples were collected using the Oracol S14 collection device by gently rubbing the swab 108 along the gumline around the entire mouth for approximately 1 minute. This collection device 109 specifically harvests gingival crevicular fluid, which resembles serum composition [14]. Saliva samples 110 collected by the Oracol swabs were separated by centrifugation (10 min at 1500 x g), transferred to the 111 attached microtube (10 µl -200 µl), and stored at -80°C until analysis. For cohort II, participants were 112 asked to cough deeply and spit into a collection cup containing virus isolation media (PBS plus 2% FBS, 113 Gentamicin, Amphotericin B). Saliva samples were clarified by centrifugation (10 min at 3000 x g), 114 aliquoted and stored at -80°C until analysis. All samples collected during the pandemic were inactivated 115 by gamma radiation (2 x 10 6 rads) prior to testing [15]. Samples were initially tested for SARS-CoV-2-116 specific salivary IgA. If enough sample volume (≥ 100µl) was available, samples were tested for SARS-

117
CoV-2-specific salivary IgG. CoV-2 spike protein were used for the initial assay development. The pre-fusion stabilized ectodomain 122 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021. ; https://doi.org/10.1101/2021.09.03.21263078 doi: medRxiv preprint of SARS-CoV-2 spike (S) that was used in the assays was obtained from in suspension adapted HEK-123 293 cells as described previously [16]. Antigen concentrations ranging from 0.125-1.00 µg/ml in PBS 124 and 1:1,000 to 1:20,000 diluted horse radish peroxidase (HRP)-conjugated goat anti-human IgA or IgG 125 were initially tested. Positive and negative controls (SARS-CoV-2 convalescent serum and pre-126 pandemic saliva samples, respectively), as well as blank controls (only blocking buffer) were also 127 included in each run. All volumes were 100 µl per well, except where indicated. All washes were   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

158
The same plate design and steps were used for IgG. Plates were coated with goat anti-human IgG 159 (γ-chain) at 0.5 µg/ml in PBS. A standard curve for IgG was prepared by serial dilutions of purified 160 human IgG (Sigma-Aldrich) and bound antibodies were detected using 1:16,000 diluted HRP-161 conjugated goat anti-human IgG (Sera Care).    This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

214
We developed and validated EIAs for the quantitative detection of SARS-CoV-2-specific 215 salivary IgA and IgG antibodies in saliva. The final assay conditions are summarized in Table 1. Pre- This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021. ; https://doi.org/10.1101/2021.09.03.21263078 doi: medRxiv preprint spike protein, anti-human IgA (α-chain) or IgG (γ-chain), HRP-labeled secondary antibody, purified 219 human IgA and purified human IgG concentration for standard curves] and incubation times were 220 optimized to reduce background, obtain maximum anti-SARS-CoV-2 specific signal, and to maximize 221 the optical density difference between pre-pandemic negative samples and SARS-CoV-2 convalescent 222 sera.  (Table 1). antibodies against SARS-CoV-2. We tested 3 dilutions for SARS-CoV-2 and total antibodies. (Table 1). This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021. ; total IgA at week 1 and increased to 7.95 (IQR: 0.1-25.74) ng/100 µg of total IgA at week 3 (IQR: 0.1-  Overall, for cohort II, the positivity rate for IgA showed a clear pattern with increasing values 295 during week 1-3, a peak at week 4, whereas the positivity rate for IgG was less defined. ( Figure 3C). 296 For patients with mild disease symptoms, the positivity rate for IgA and IgG was 33.3% at week 1 after 297 onset of symptoms. The IgA titer rapidly increased and peaked at week 4 (100%), sharply decreased to 298 0% at week 9 and remained negative until week 30. The positivity rate for IgG peaked at 50% at week 3, 299 fluctuated for several weeks and returned to 0% 30 weeks after onset of disease. In patients with severe 300 clinical symptoms, the positivity rate for IgA and IgG were consistently higher than in mild cases at  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021. ; 12 315 DISCUSSION 316 We report the development and validation of in-house EIAs to quantitatively assess the presence 317 of SARS-CoV-2-specific IgA and IgG in saliva and showed its value to describe the salivary immune This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021. ; group found similar IgG and IgA kinetics in serum from mild and severe cases [20]. Several studies 347 reported higher correlation for IgG than IgA when testing paired serum and saliva samples [8,9], 348 leading to question the advantage of testing IgA in saliva. Early SARS-CoV-2 humoral immune  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021. ; participants. We are also grateful to Peter Sullivan, Matthew Strnad, Felicity Coulter, and Sarah Siegel 378 for logistical and administrative support for patient consent and sample processing at OHSU.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021. ;  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021. ;  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted September 7, 2021.